Tempus AI, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Lefkofsky
- Full Time Employees
- 3,800
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 600 West Chicago Avenue Chicago IL United States of America 60654
- IPO Date
- Jun 14, 2024
- CIK
- 0001717115
- Website
- tempus.com
- Similar Companies
- Business
- Tempus AI, Inc. operates as an innovative healthcare technology firm, dedicated to transforming patient care through the application of artificial intelligence. The company specializes in delivering comprehensive genomic sequencing diagnostics, including next-generation sequencing, polymerase chain reaction profiling, and advanced molecular pathology testing to a broad spectrum of healthcare entities. These clients include medical providers, pharmaceutical manufacturers, biotechnology innovators, and research institutions. The organization provides a suite of advanced platforms such as Tempus Lens, designed for scientists to explore, access, and analyze de-identified clinical, molecular, and imaging data, and Tempus Hub, a streamlined desktop and mobile interface for managing test orders and patient results. Their offerings also encompass predictive algorithmic tests, like Algos and Next, tailored for oncology and other therapeutic areas, as well as Trials, a service that facilitates patient matching for clinical studies. Tempus AI generates revenue primarily through its genomic testing services, data licensing, and clinical trial solutions. The company notably expanded its reach by going public on Nasdaq in June 2024 under the ticker TEM. Recent strategic developments include the November 2024 acquisition of Ambry Genetics, a $600 million deal, and the formation of SB Tempus, an AI healthcare joint venture in Japan with SoftBank. In April 2025, Tempus AI, AstraZeneca, and Pathos AI announced multi-year agreements, including $200 million in data licensing and model development fees to Tempus, to co-develop a significant multimodal foundation model in oncology, building on an earlier 2021 partnership. Further collaborations in 2025 include a partnership with Illumina for genomic testing integration and research alliances with Northwestern University for Alzheimer's disease and the Institute for Follicular Lymphoma Innovation. Headquartered in Chicago, Illinois, Tempus AI was established in 2015 and remains at the forefront of leveraging large-scale multimodal data and AI to accelerate precision medicine, with a significant presence among U.S. oncologists and top biopharma companies.
3 Powerful AI Stocks Poised for the Next Massive Shift
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus AI, Inc. $TEM Stake Boosted by Amova Asset Management Americas Inc.
Cathie Wood's Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Tempus AI: Building Ultimate Healthcare Data Dominance
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now